Page 2097 - Williams Hematology ( PDFDrive )

2072 Part XII: Hemostasis and Thrombosis <CN>: <ct> PB

560. Favier R, Jondeau K, Boutard P, et al: Paris-Trousseau syndrome: Clinical, hematologi- 588. Kobrinsky NL, Israels ED, Gerrard JM, et al: Shortening of bleeding time by 1-deamino-
cal, molecular data of ten new cases. Thromb Haemost 90:893–897, 2003. 8-d-arginine vasopressin in various bleeding disorders. Lancet 1:1145–1148, 1984.
561. Raslova H, Komura E, Le Couedic JP, et al: FLI1 monoallelic expression combined with 589. Schulman S, Johnson H, Egberg N, Blombäck M: DDAVP-induced correction of pro-
its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest longed bleeding time in patients with congenital platelet function defects. Thromb Res
114:77–84, 2004. 45:165–174, 1987.
562. Shivdasani RA: Lonely in Paris: When one gene copy isn’t enough. J Clin Invest 114: 590. DiMichele DM, Hathaway WE: Use of DDAVP in inherited and acquired platelet
17–19, 2004. dysfunction. Am J Hematol 33:39–45, 1990.
563. Kurstjens R, Bolt C, Vossen M, Haanen C: Familial thrombopathic thrombocytopenia. 591. Nieuwenhuis HK, Sixma JJ: 1-Desamino-8-d-arginine vasopressin (Desmopressin)
Br J Haematol 15:305–317, 1968. shortens the bleeding time in storage pool deficiency. Ann Intern Med 108:65–67, 1988.
564. Estes JW: Platelet abnormalities in heritable disorders of connective tissue. Ann N Y 592. Colucci G, Stutz M, Rochat S, et al: The effect of desmopressin on platelet function: A
Acad Sci 201:445–450, 1972. selective enhancement of procoagulant COAT platelets in patients with primary plate-
565. Evensen SA, Myhre L, Stormorken H: Haemostatic studies in osteogenesis imperfecta. let function defects. Blood 123:1905–1916, 2014.
Scand J Haematol 33:177–179, 1984. 593. Almeida AM, Khair K, Hann I, Liesner R: The use of recombinant factor VIIa in
566. Akkerman JWN, Rijksen G, Gorter G, al e. Platelet functions and energy metabolism in children with inherited platelet function disorders. Br J Haematol 121:477–481, 2003.
a patient with hexokinase deficiency. Blood 63:147–153, 1984. 594. Poon MC, d’Oiron R. Recombinant activated factor VII (NovoSeven) treatment of
567. Corby DG, Putnam CW, Greene HL: Impaired platelet function in glucose- platelet-related bleeding disorders. International Registry on Recombinant Factor
6-phosphatase deficiency. J Pediatr 85:71–76, 1974. VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 11 (Suppl 1:)
568. Czapek EE, Deykin D, Salzman EW: Platelet dysfunction in glycogen storage disease S55–S68, 2000.
type I. Blood 41:235–247, 1973. 595. Poon MC, Demers C, Jobin F, Wu JW: Recombinant factor VIIa is effective for bleed-
569. Boullin DJ, O’Brien RA. Abnormalities of 5-hydroxytryptamine uptake and binding by ing and surgery in patients with Glanzmann thrombasthenia. Blood 94:3951–3953,
blood platelets from children with Down’s syndrome. J Physiol 212:287–297, 1971. 1999.
570. Lott IT, Chase TN, Murphy DL: Down’s syndrome: Transport, storage, and metabolism 596. del Pozo Pozo AI, Jimenez-Yuste V, Villar A, et al: Successful thyroidectomy in a patient
of serotonin in blood platelets. Pediatr Res 6:730–735, 1972. with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and
571. McCoy EE, Sneddon JM: Decreased calcium content and 45Ca2+ uptake in Down’s platelet concentrates. Blood Coagul Fibrinolysis 13:551–553, 2002.
syndrome blood platelets. Pediatr Res 18:914–916, 1984. 597. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blomback M: Hemostatic effect of tranex-
572. More R, Amir N, Meyer S, et al: Platelet abnormalities in Down’s syndrome. Clin Genet amic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl
22:128–136, 1982. J Med 320:840–843, 1989.
573. Sheppard JR, Schumacher W, White JG, et al: The alpha adrenergic response of Down’s 598. Mielke CH Jr, Levine PH, Zucker S: Preoperative prednisone therapy in platelet func-
syndrome platelets. J Pharmacol Exp Ther 225:584–588, 1983. tion disorders. Thromb Res 21:655–662, 1981.
574. Hamilton RW, Shaikh BS, Ottie JN, et al: Platelet function, ultrastructure, and survival 599. Spotnitz WD, Burks S: Hemostats, sealants, and adhesives: Components of the surgical
in the May-Hegglin anomaly. Am J Clin Pathol 74:663–668, 1980. toolbox. Transfusion 48:1502–1516, 2008.
575. Lusher JM, Schneider J, Mizukami I, et al: The May-Hegglin anomaly: Platelet function, 600. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al: Recombinant activated
ultrastructure and chromosome studies. Blood 32:950–961, 1968. factor VII combined with local measures in preventing bleeding from invasive dental
576. Coller BS, Zarrabi MH: Platelet membrane studies in the May-Hegglin anomaly. Blood procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 14:
58:279–284, 1981. 187–190, 2003.
577. Freson K, Hashimoto H, Thys C, et al: The pituitary adenylate cyclase-activating poly- 601. Singla NK, Foster KN, Alexander WA, Pribble JP: Safety and immunogenicity
peptide is a physiological inhibitor of platelet activation. J Clin Invest 113:905–912, of recombinant human thrombin: A pooled analysis of results from 10 clinical trials.
2004. Pharmacotherapy 32:998–1005, 2012.
578. Sandrock K, Nakamura L, Vraetz T, et al: Platelet secretion defect in patients with 602. Wilcox DA, Olsen JC, Ishizawa L, et al: Integrin alphaIIb promoter-targeted expres-
familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Blood 116:6148–6150, sion of gene products in megakaryocytes derived from retrovirus-transduced human
2010. hematopoietic cells. Proc Natl Acad Sci U S A 96:9654–9659, 1999.
579. Al Hawas R, Ren Q, Ye S, et al: Munc18b/STXBP2 is required for platelet secretion. 603. Wilcox DA, White GC 2nd: Gene therapy for platelet disorders: Studies with
Blood 120:2493–2500, 2012. Glanzmann’s thrombasthenia. J Thromb Haemost 1:2300–2311, 2003.
580. Ye S, Karim ZA, Al Hawas R, et al: Syntaxin-11, but not syntaxin-2 or syntaxin-4, is 604. Fang J, Jensen ES, Boudreaux MK, et al: Platelet gene therapy improves hemostatic
required for platelet secretion. Blood 120:2484–2492, 2012. function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A 108:
581. Alamelu J, Liesner R: Modern management of severe platelet function disorders. Br 9583–9588, 2011.
J Haematol 149:813–823, 2010. 605. Hodivala-Dilke KM, Tsakiris DA, Rayburn H, et al: Beta3-integrin-deficient mice are a
582. Seligsohn U: Treatment of inherited platelet disorders. Haemophilia 18 (Suppl 4:) model for Glanzmann thrombasthenia showing placental defects and reduced survival.
161–165, 2012. J Clin Invest 103:229–238, 1999.
583. Bolton-Maggs PH, Chalmers EA, Collins PW, et al: A review of inherited platelet disor- 606. Boudreaux MK, Lipscomb DL: Clinical, biochemical, and molecular aspects of
ders with guidelines for their management on behalf of the UKHCDO. Br J Haematol Glanzmann’s thrombasthenia in humans and dogs. Vet Pathol 38:249–260, 2001.
135:603–633, 2006. 607. Niemeyer GP, Boudreaux MK, Goodman-Martin SA, et al: Correction of a large
584. Fiore M, Firah N, Pillois X, et al: Natural history of platelet antibody formation against animal model of type I Glanzmann’s thrombasthenia by nonmyeloablative bone marrow
alphaIIbbeta3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia transplantation. Exp Hematol 31:1357–1362, 2003.
18:e201–9, 2012. 608. Schlosser RJ: Clinical practice. Epistaxis. N Engl J Med 360:784–789, 2009.
585. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: The 609. Siddiq S, Clark A, Mumford A: A systematic review of the management and outcomes
first 20 years. Blood 90:2515–2521, 1997. of pregnancy in Glanzmann thrombasthenia. Haemophilia 17:e858–e869, 2011.
586. Mannucci PM: Hemostatic Drugs. N Engl J Med 339:245–253, 1998. 610. Peitsidis P, Datta T, Pafilis I, et al: Bernard Soulier syndrome in pregnancy: A systematic
587. Rao AK, Ghosh S, Sun L, et al: Effect of mechanism of platelet dysfunction on response review. Haemophilia 16:584–591, 2010.
to DDAVP in patients with congenital platelet function defects. A double-blind 611. Coller BS: Inherited disorders of platelet function, in Hemostasis and Thrombosis,
placebo-controlled trial. Thromb Haemost 74:1071–1078, 1995. edited by AL Bloom, p. 721–766. Churchill Livingstone, Edinburgh, 1992.

Kaushansky_chapter 120_p2039-2072.indd 2072 9/21/15 2:22 PM